CORRECTION: HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals (1-for-10 Reverse Stock Split) - Headline Earlier Published on 9th Aug
Portfolio Pulse from vivek@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) following a 1-for-10 reverse stock split.
August 13, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) following a 1-for-10 reverse stock split.
The maintenance of a Buy rating by a reputable analyst following a reverse stock split is a positive signal for investors, indicating confidence in the company's future performance despite the equity action.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100